Product Description
(Sourced from: https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Zhejiang Saimo Pharmaceutical Co., Ltd.
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Ischemic Stroke
Phase 0: Unknown
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20260969 |
CTR20260969 | P1 |
Unknown |
Ischemic Stroke |
None |
2026-04-28 |
Patient Enrollment|Start Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|